# Council memo — 2026-08-24

*Structured synthesis of this system's own analyst agents. Not advice from a
licensed advisor. Every number below traces to a file fetched or maintained in
this repo; nothing is estimated from memory.*

Snapshot: `data/cache/snapshots/20260824T060950.json` · Screen:
`data/cache/screens/20260824T061349-digest.csv` · Calendar:
`data/cache/calendar/20260824-events.json`

---

## 1. Position report

| Position | Price | Δ vs prev snapshot | Δ vs cost | 52w range | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A (stock) | 146.05 | -1.6% | +13.0% | 89% | 146.05 | fetched |
| Investor A (stock) | 405.40 | -0.2% | +39.7% | 90% | 2,027.00 | fetched |
| Volvo B | 340.00 | -0.8% | -7.5% | 73% | 4,420.00 | fetched |
| Atlas Copco B | 175.50 | -2.8% | -3.2% | 81% | 4,738.50 | fetched |
| AstraZeneca | 1,560.50 | +4.8% | +3.4% | 35% | 7,802.50 | fetched |
| Alfa Laval | 548.40 | -1.9% | -4.5% | 74% | 4,935.60 | fetched |
| ABB | 943.80 | -3.1% | -0.3% | 74% | 3,775.20 | fetched |
| Avanza Auto 3 (fund) | no data | no data | +65.2% | - | 16,191.00 | book value |
| Avanza Global (fund) | no data | no data | +0.0% | - | 119,999.00 | book value |
| Valour Bitcoin Zero SEK (certificate, ISIN CH0585378661) | no data | no data | +0.0% | - | 9,183.00 | user-relayed |
| ETH (self-custody wallet) | 23,070.37 | +27.4% | no data | - | 11,577.86 | fetched (CoinGecko, converted via sek_per_eur) |

*52w range: 0% = at the 52-week low, 100% = at the 52-week high.*

| Coin | Price (EUR) | Δ vs prev snapshot | 7d | 30d | vs ATH |
|---|---|---|---|---|---|
| bitcoin | 66,017.00 | +18.8% | +21.6% | +20.3% | -38.7% |
| ethereum | 2,094.26 | +27.4% | +28.8% | +31.6% | -50.5% |

**Reading it.** One position moved enough to matter and it is the one the
Council has been recommending for three sweeps: **AstraZeneca +4.8%**, now
+3.4% above blended cost (1,509.70) for the first time. Every other equity
fell 0.2-3.1% — a broad, small down-week for the Swedish industrial cluster
(ATCO-B -2.8%, ABB -3.1%, ALFA -1.9%), not a company-specific event in any of
them. **Crypto is the week's real move: BTC +18.8%, ETH +27.4% in six days.**
That is a ~2,500 SEK gain on the ETH wallet and it did *not* trigger the crypto
trip-wire (9.37% vs the 10% target) because the position was underweight going
in.

**Does any move contradict a thesis?** One does, mildly, and in the good
direction: ETH's thesis file cites Fear&Greed at 29 ("Fear") as evidence the
position is on the wrong side of the regime. That input has flipped to 73
("Greed") — the thesis isn't broken (it was never regime-dependent), but the
stored `key_risks` text is now factually stale and should be rewritten at next
full review. No move contradicts a thesis in the bad direction. AZN's move
*confirms* its thesis while making the unexecuted BUY incrementally more
expensive each sweep. Broad index funds (Avanza Global, Auto 3): no NAV feed,
no action, buy-and-hold by design.

---

## 2. Top opportunities — Stock Selection Council

**Universe:** 11 held tickers (excluding cash, tax reserve, and the frozen SEB
Osteuropafond) + 43 screen entries, all three statuses. Six independent analyst
passes ran first; the Chairman's synthesis follows. Portfolio fit is applied
*after* the merit ranking, never before it.

### Chairman's Top 5

```
#1 OPPORTUNITY: AZN.ST — AstraZeneca
TYPE: existing holding (5 sh, 7,802.50 SEK, 3.52% of portfolio)
AGENTS IN FAVOR: Defensive (8: beta 0.211 and ND/EBITDA 1.38 make it the only
        genuine downside ballast in the book); Valuation (7: PEG 1.44, sits at
        35% of its 52-week range while every other held equity sits at 73-90%);
        Macro (7: low-beta healthcare is exactly what a VIX-16 / restrictive-
        Swedish-real-rate regime rewards, and cheap volatility is when ballast
        is worth buying); Contrarian (6: the only unloved name in a book of
        near-highs); Quality (5: ROE 22.0 / ROIC 13.1 / margin 17.0 are good,
        not elite — it is a solid business, not the best one in the universe)
AGENTS AGAINST / CAUTIOUS: Growth (6.4% revenue growth is the second-slowest of
        anything picked this sweep; this is not a compounder story)
STRONGEST CASE FOR: Defensive — this is the only holding whose price behaviour
        this sweep (+4.8% on a week when six of seven equities fell) matched
        the property its thesis actually claims. A thesis you have watched
        behave is worth more than one you have asserted.
STRONGEST CASE AGAINST: Growth — buying the fourth-cheapest-on-PEG name in a
        universe that contains META at PEG 0.82 with 28% revenue growth is
        paying for safety, and you should know that is what you are doing.
DATA GAPS: no forward P/E for AZN.ST anywhere in this sweep (digest status
        MISSING on exactly that field) — so the single cheapest check available
        elsewhere in this memo, forward-vs-trailing multiple, cannot be run on
        the name being bought. Discount confidence one notch, not more: PEG,
        margins, four years of rising revenue and the 47.4% payout ratio are
        all present and all point the same way.
CHAIRMAN CONVICTION: 8
MAJOR UNCERTAINTY: whether the ~19%-off-the-high discount is sector sentiment
        (valuation's read) or the market pricing something in the pipeline this
        system cannot see. Free data cannot distinguish these.
FINAL CALL: BUY — add 3 shares at ~1,560.50 = ~4,682 SEK
PORTFOLIO-FIT REASONING: portfolio rates Healthcare 28.0% of the stock sleeve
        (OK) against Industrials 64.2% (ACT) and Sweden 58.4% (ACT); AZN is
        UK-HQ'd, so this add moves both ACT-rated rows in the right direction.
        Capital: verified against this sweep's portfolio output — 11,288 SEK
        broker-confirmed ISK cash (2026-08-23), zero tax event inside the ISK,
        4,682 SEK leaves 6,606 SEK. Post-trade AZN is ~5.6% of total portfolio,
        well inside the 15% single-position cap and inside the "normal" 3-8%
        band. This is portfolio's own rebalancing action (b) executed against
        the best-argued name rather than the index fund.
HORIZON: Long
```

```
#2 OPPORTUNITY: ABB.ST — ABB
TYPE: existing holding (4 sh, 3,775.20 SEK, 1.70% of portfolio)
AGENTS IN FAVOR (of holding): Quality (ROE 32.6 / ROIC 20.6 / 14.2% revenue
        growth is a genuinely good business — this is not a distressed name);
        Growth (14.2% ttm revenue growth is real and is the fastest of the four
        held industrials)
AGENTS AGAINST / CAUTIOUS: Valuation (P/E 36.8 with forward P/E barely moving
        to 35.9 despite 14.2% growth — that flat forward multiple is the market
        pricing margin compression, not a re-rating); Defensive (beta 1.011,
        margin 14.1%, and it thickens an already-ACT-rated industrials cluster);
        Macro (Swedish/Nordic industrial into a +1.45% real Riksbank rate);
        Contrarian (nothing contrarian here — 74% of range, consensus-held,
        richly priced)
STRONGEST CASE FOR (holding): Quality — ABB scores 51/100 on
        `swedish-equity-review` but so does a lot of the market; 32.6% ROE is
        top-quartile in this universe and selling a good business to solve a
        concentration number is a real cost.
STRONGEST CASE AGAINST: Valuation — flat forward P/E against double-digit
        revenue growth is the clearest single negative signal in the entire
        held book, and it has now been visible for three consecutive sweeps
        without improving.
DATA GAPS: ABB's raw P/S (48x) and P/B (108x) in the snapshot are confirmed
        USD/SEK currency artifacts — use the FX-corrected ~5.2x / ~11.7x in
        `data/company_profiles/ABB.ST.json`, which is dated 2026-08-17 and
        could use a refresh. `fcf_b` 1.57 against `mcap_b` 1715.4 is
        cross-currency and therefore not a usable FCF yield (S17).
CHAIRMAN CONVICTION: 6
MAJOR UNCERTAINTY: whether ABB's next reported fiscal quarter converts the
        14.2% revenue growth into earnings. If it does, the flat forward P/E
        was an estimate error and this sell is wrong.
FINAL CALL: SELL — all 4 shares, ~3,775 SEK proceeds
PORTFOLIO-FIT REASONING: this is the call that funds #3 without touching cash.
        ABB is one of the four names inside portfolio's ACT-rated Industrials
        64.2% and its Switzerland-HQ line is the smallest of the three country
        buckets; removing it takes Industrials to roughly 50% of the sleeve.
        Wrapper: ISK — no capital-gains event, and the position is -0.3% vs
        cost, so this is a return of capital, not a realized gain. That matters
        procedurally: `profit_recycling_rule` (gains from medium/high tiers
        flow to the secure tier) does **not** bite here, so redeploying into
        another medium-tier equity is compliant, not an override. Courtage is
        the only cost.
HORIZON: Medium
```

**Why this escalates from HOLD-WATCH now, when the insider signal just went
quiet.** Two prior sweeps held ABB specifically because its written break
condition ("insider selling continues into a second FI pull") had never been
tested. It was tested 2026-08-23 and did **not** trigger — the pattern went
quiet. That closes the insider leg in ABB's *favour*. The sell does not rest on
it. It rests on the *other* clause of the same break condition, written the
same morning from real data: *"re-test if a materially better-positioned
Nordic-industrial alternative surfaces via screening."* This sweep's screen
surfaced materially better-positioned alternatives (see #3), and the condition
has now been sitting satisfiable for three sweeps. Either the condition fires
or it should be rewritten — three sweeps of HOLD-WATCH on a condition that
keeps almost-firing is the pattern this system has already been burned by
elsewhere.

```
#3 OPPORTUNITY: META — Meta Platforms
TYPE: new candidate (not currently held individually; present inside Avanza
        Global, which per the 2026-08-17 standing rule is explicitly NOT a
        reason to de-prioritize it)
AGENTS IN FAVOR: Growth (9: 28.0% revenue growth with the forward multiple
        *falling* from 20.70 to 15.85 — consensus says earnings are climbing
        fast, the single most informative pattern in this digest); Valuation
        (8: PEG 0.82, the lowest of any name that also cleared the screen, and
        the only mega-cap where forward P/E is below 16); Quality (6: ROE 29.8,
        ROIC 18.6, margin 29.8, ND/EBITDA 0.20 — strong, though GOOGL and MSFT
        are better on every one of those); Contrarian (4: not contrarian at
        all, and said so)
AGENTS AGAINST / CAUTIOUS: Macro (4, and this is an explicit regime downgrade
        of a fundamentally strong name, stated plainly rather than buried:
        buying a USD-revenue asset with kronor at DXY 118.9 is taking a
        currency bet you are not paid to take, on top of the equity bet you
        are); Defensive (beta 1.243 — this amplifies market moves and adds no
        downside protection to a book that has almost none)
STRONGEST CASE FOR: Growth — 28% revenue growth and a forward multiple 24%
        below trailing is a combination that appears exactly once in this
        43-name universe outside the semiconductor names the screen rejected
        on trailing P/E.
STRONGEST CASE AGAINST: Macro — the FX objection is real and unhedgeable at
        this portfolio size, and it is the same objection this voice raised
        against GOOGL on 2026-08-18. Consistency matters; it is not being
        waved through because the fundamentals are nicer this time.
DATA GAPS: `fcf_b` 21.55 against `mcap_b` 1400.9 implies a 1.54% FCF yield,
        which is too low to be credible for this business — the digest's FCF
        and market-cap fields are not on a consistent currency basis (S17,
        fix identified in code). Treat the FCF-yield column as unusable this
        sweep; the pick rests on PEG, forward multiple and growth, all of which
        are internally consistent. No earnings-revision or TAM data exists
        anywhere in this system — the "consensus expects earnings up" reading
        is inferred from the forward/trailing gap, not fetched.
CHAIRMAN CONVICTION: 7
MAJOR UNCERTAINTY: whether the forward-P/E compression reflects genuine
        earnings acceleration or a capex cycle that flatters near-term
        estimates. One reported quarter resolves it.
FINAL CALL: BUY — 1 share at 545.83 USD (~5,200 SEK at the ~9.5 SEK/USD
        implied by portfolio's own PayPal valuation; verify the live rate at
        execution, this system did not restate FX this sweep)
PORTFOLIO-FIT REASONING: portfolio's candidate one-liners say Communication
        Services and non-Nordic both diversify, and this is the only Top-5 buy
        that hits both. It does not fix the 100% large-cap WATCH row (META is
        large-cap; nothing that fixes that row surfaced this sweep worth
        buying). Capital: funded by #2's ABB proceeds (3,775 SEK) plus ~1,425
        SEK of the 11,288 broker-confirmed ISK cash remaining after #1 — no
        new money required, no PayPal dependency. Medium tier is materially
        underfilled (individual stocks 12.6% of portfolio vs a 30% tier
        target), so adding an individual name rather than more index fund is
        the correct direction under the risk-tier framework. Post-trade both
        ACT-rated rows improve and equity moves 71.11% → ~73.9%.
HORIZON: Medium
```

```
#4 OPPORTUNITY: VOLV-B.ST — Volvo B
TYPE: existing holding (13 sh, 4,420.00 SEK, 2.00% of portfolio) — and the
        only current holding that PASSED scout's screen outright
AGENTS IN FAVOR: Valuation (6: forward P/E 13.77 against trailing 19.46, PEG
        1.43, and — uniquely in this digest — an FCF-yield proxy that is
        actually usable because both FCF and market cap are SEK, giving ~3.4%);
        Growth (5: ttm revenue growth turned positive at +2.7% after two
        declining fiscal years, which is the recovery the insider purchase bet
        on); Contrarian (5: at 73% of its 52-week range it is the cheapest-
        positioned held industrial)
AGENTS AGAINST / CAUTIOUS: Defensive (**SELL, and this is the strongest single
        SELL argument produced by any voice this sweep**: D/E 147.3 and
        net-debt/EBITDA 3.8 are the highest leverage of any operating company
        in the entire 43-name universe, on a 7.6% profit margin — the thinnest
        of anything held — going into a Swedish real policy rate of +1.45%);
        Macro (a domestic-cycle Swedish industrial is precisely the profile a
        restrictive domestic real rate punishes); Quality (7.6% margin and
        ROIC 9.7 are the weakest quality figures in the held book)
STRONGEST CASE FOR: Valuation — the forward multiple compression is real, the
        FCF yield is one of only two in this digest that survives the currency
        problem, and thesis-review confirms the position is 3 weeks into a
        stated 3-month test window that has not been falsified.
STRONGEST CASE AGAINST: Defensive — 3.8x net-debt/EBITDA on a 7.6% margin
        cyclical is not a valuation discount, it is the thing that makes the
        downside non-linear. If the recovery stalls, leverage does the damage
        before the multiple does.
DATA GAPS: no updated fiscal-quarter data since the thesis was written, so the
        recovery leg is untested in either direction. Insider data for Swedish
        names is user-relayed/fetched ad hoc, not refreshed this sweep.
CHAIRMAN CONVICTION: 6 (on holding, not on adding)
MAJOR UNCERTAINTY: the next reported quarter. The whole disagreement between
        Valuation and Defensive collapses to whether the +2.7% ttm turn is the
        start of the recovery or a base effect.
FINAL CALL: HOLD-WATCH — no add, no sell. Test window runs to ~2026-11-03.
PORTFOLIO-FIT REASONING: portfolio's Industrials row is ACT at 64.2%; adding to
        Volvo worsens the one thing the rest of this memo is trying to fix,
        which independently rules out the add regardless of the valuation case.
        Selling it, conversely, would mean abandoning a thesis 3 weeks into its
        own stated 3-month window on no new company data — the exact
        undisciplined behaviour a written break condition exists to prevent.
        The honest answer is that both of the actions are blocked, one by
        concentration and one by process, so the correct output is neither.
HORIZON: Medium
```

```
#5 OPPORTUNITY: GOOGL — Alphabet
TYPE: new candidate (not currently held individually) — and last sweep's #2
AGENTS IN FAVOR: Quality (9: the best composite quality profile in the entire
        universe that also clears the screen — ROE 48.7, ROIC 28.6, margin
        54.8%, and net cash at -0.7x net-debt/EBITDA); Valuation (7: PEG 0.93);
        Growth (6: 24.2% revenue growth)
AGENTS AGAINST / CAUTIOUS: Valuation also flags the tension it created (forward
        P/E 23.28 is *above* trailing 17.30 — consensus expects earnings to
        fall, which is the opposite signal to META's); Macro (same DXY 118.9
        FX objection as #3, raised against this exact name on 2026-08-18);
        Defensive (beta 1.237)
STRONGEST CASE FOR: Quality — on business quality alone this is the best
        company in the candidate universe and it is not close. If the question
        were "what would you own for ten years," this wins.
STRONGEST CASE AGAINST: Valuation's own forward/trailing check. GOOGL 17.30 →
        23.28 and META 20.70 → 15.85 are pointing in opposite directions on
        the same metric. You cannot buy both on the same reasoning, and the
        one whose estimates are rising is the better *investment* this sweep
        even though it is the worse *business*. That distinction is the entire
        reason the Valuation voice exists separately from the Quality voice.
DATA GAPS: the 54.8% profit margin is high enough to suggest a non-recurring
        item in trailing earnings, which would also explain the forward-P/E
        step-up — but no multi-year margin series is in the digest to confirm
        it. Same S17 FCF-currency problem as #3 (22.67/4217.1 = 0.54%, not
        credible).
CHAIRMAN CONVICTION: 5
MAJOR UNCERTAINTY: what is inside the trailing margin. If the 54.8% is clean
        recurring margin, the forward step-up is estimator conservatism and
        GOOGL outranks META. If it is a one-off, the market is right.
FINAL CALL: HOLD-WATCH
PORTFOLIO-FIT REASONING: **this is an explicit reversal of the 2026-08-18
        memo, and P3's own note in OPEN_ITEMS.md needs updating because of
        it.** That note earmarks the PayPal conversion proceeds for GOOGL. On
        this sweep's data META is the better-supported use of the same money
        (PEG 0.82 vs 0.93, forward multiple falling vs rising, 28.0% vs 24.2%
        revenue growth), and the portfolio-fit case is identical — both are
        Communication Services, both are non-Nordic, both are large-cap. There
        is no reason to hold two positions in the same sector/geography/
        market-cap cell at a 27,845 SEK sleeve size. Buy one. This sweep says
        META.
HORIZON: Medium
```

### Other current-holding SELL flags (not in the Top 5)

The user gets a direct answer to "should I sell anything" every sweep, not only
when a sell ranks top-5.

- **SHB-A.ST — SELL on merit, but the size makes it noise.** Both Growth and
  Valuation flagged it: revenue -3.8%, forward P/E (12.9) *above* trailing
  (12.3), consensus "underperform", price at 97.6% of its 52-week range,
  thesis-review says the break condition is "effectively already satisfied."
  This is a genuine sell. It is also **one share worth 146.05 SEK** — 0.07% of
  the portfolio. Courtage on a 146 SEK order is a meaningful fraction of the
  proceeds. **Concrete action: sell it the next time you are placing an order
  anyway** (e.g. alongside the ABB sale in #2), not as a standalone trade.
- **INVE-A.ST — HOLD, and the reason is missing data, not confidence.**
  Contrarian flagged it again (2,027 SEK, 96.9% of its 52-week range, and per
  its own thesis file the "upside" cited at purchase is captured). It stays a
  hold only because the metric that would settle it — NAV discount/premium —
  has never been obtained (S6, second consecutive sweep this exact gap has
  blocked a real call). That is a data problem with a known fix, not an
  argument for the position.
- **ATCO-B.ST, ALFA.ST — HOLD, no adds.** Both WEAKENING, both expensive
  (PEG 2.34 and 2.88), neither has new fiscal-quarter data to test. ALFA has
  the strongest evidence of the three P6 industrials (63/100, 10/10 insider
  buys, zero disposals) and is not the rotation candidate; ATCO-B sits at 81%
  of range with a thin single-insider signal. No voice argued to sell either
  ahead of ABB.
- **ETH and the Valour BTC certificate — HOLD, explicit no-add.** Macro's
  froth warning is the binding input: Fear&Greed 29 → 73 in under two weeks on
  a straight-line +20-30% move, against a strong dollar that is historically a
  crypto headwind. Crypto is at 9.37% vs a 10% target — 0.63pp is not a
  rebalancing trigger. Adding to ETH is separately blocked by P1 (no cost
  basis; every disposal including a token swap is a K4 event).
- **Two new names worth a WATCH, neither underwritable today.** **EVO.ST**
  (Evolution AB) is the most interesting thing the Contrarian voice found:
  51.8% profit margin, ROIC 22.4%, essentially no debt (D/E 2.13, net cash at
  -0.85x), P/E 13.9 falling to 11.4 forward, 5.05% dividend — and it failed
  scout on a -1.2% revenue wobble. That profile normally does not trade at 14x.
  The reason it does is regulatory, and **this system fetches no regulatory
  data at all**, so the one thing that would decide the call is the one thing
  missing. WATCH, not BUY. **NOVO-B.CO** failed the screen on PEG 3.18 alone
  while carrying the best quality metrics in the universe (ROE 59.8, ROIC 35.6,
  margin 35.3, beta 0.349) — same conclusion as 2026-08-18, and still blocked
  by the same missing SEK/DKK rate.

---

## 3. Portfolio health scorecard

Carried verbatim from this sweep's `portfolio` agent.

| Dimension | Status | Detail |
|---|---|---|
| Asset allocation vs targets (85/10/5/0) | **WATCH** | equity 71.11% (-13.89pp), cash 16.60% (+11.60pp), crypto 9.37% (-0.63pp), FI-within-fund 2.92% (+2.92pp). Gap is mostly already-decided-but-unexecuted (P3 + deploying idle ISK cash), not a fundamental mismatch. |
| Equity sector concentration | **ACT** | Industrials 64.2% of the individual-stock sleeve (VOLV+ATCO+ALFA+ABB, 17,869/27,845 SEK). |
| Geography (home bias) | **ACT** | Sweden 58.4% of individual-stock sleeve. |
| Currency exposure (revenue-basis) | **UNKNOWN** | No per-company revenue-by-region data. |
| Single-position concentration | **OK\*** | Largest single company AZN.ST 3.52%; largest fund Avanza Global 54.15% (diversified index fund, not single-company risk, flagged separately). |
| Institution concentration | **ACT** (no action) | Avanza 83.27% of total vs an 80% cap — byproduct of correctly-executed ISK consolidation; non-Avanza balances are a tax reserve, decided-pending-conversion cash, and a self-custody wallet, not alternative investment accounts. |
| Fee drag | **OK** | 183.14 SEK/yr = 0.083% of total (cap 0.4%). |
| Wrapper efficiency | **OK** | ISK ~184,506 SEK vs the ~300k threshold; only non-ISK security is the frozen SEB Osteuropafond. |
| Drawdown-tolerance fit | **OK (provisional)** | Backtested target max drawdown -19.95% vs -30% tolerance (S5, closed 2026-08-17); single 86-month window excluding 2008, no fees/tax/FX modeled. |

**Expanded diversification breakdown** (scope: individual-stock sleeve only,
27,844.85 SEK / 12.6% of total — Avanza Global 54.2% and Auto 3 7.3% have **no
look-through data**, a confirmed standing gap):

- **Industry:** Industrials 64.2% (ACT), Healthcare 28.0% (OK), Financial
  Services 7.8% (OK).
- **Country:** Sweden 58.4% (ACT), UK 28.0% (AZN), Switzerland 13.6% (ABB).
- **Market-cap tier:** all 7 individually-picked names are large-cap. **Zero
  mid- or small-cap exposure (WATCH.)** Nothing this sweep fixes this row, and
  nothing worth buying purely to fix it surfaced.
- **ESG/sustainability:** no ESG field exists anywhere in this sweep's fetched
  data for any holding or candidate. Stated as "no ESG data," not estimated.

**Is the scorecard provisional?** Partly. `investor_profile.json` has no hard
TBDs blocking it, but two fields are soft and one is unanswered:
`horizon.primary_goal` is explicitly uncertain, `years_until_needed` is "3-7
SOFT, not committed," and `constraints.exclusions` is empty with "None stated
yet" — which is why the ESG row can only ever read UNKNOWN rather than
PASS/FAIL. Unanswered question: **do you have any exclusions (sectors,
countries, ESG lines) you would not own?** Nobody has ever asked.

### Target allocation status

**No re-derivation needed and none done.** `reference_targets` are populated,
not null: **85% equity / 10% crypto / 5% cash / 0% fixed income**, adopted
2026-07-27, written into `portfolio.json.targets` 2026-08-03, and backtested
2026-08-17 (S5, closed: -19.95% max drawdown against the -30% tolerance, on one
real 86-month window that excludes 2008 — clears the bound, not exhaustively
validated).

**Glidepath re-anchor trigger: NOT fired.** The trigger is the property goal
firming up with a date inside ~3 years.
`investor_profile.json.horizon.years_until_needed` still reads "3-7 (SOFT —
goal not committed)" and `primary_goal` still reads "nature UNCERTAIN." Nothing
changed this sweep. **The 85/10/5/0 target stands unchanged.**

### Structural levers 1-2 — nothing broke

Wrapper: OK. Fee drag: 0.083%. Both closed as of 2026-08-03, both still closed.
No further comment, by design.

### Blocking-question check

**None.** The scheduled task that launched this sweep assumed the Handelsbanken
wrapper question is still open and must lead the memo. That premise is stale —
resolved 2026-07-07, account fully exited, and CLAUDE.md states plainly that no
item currently holds blocking status. Following CLAUDE.md, which overrides.

---

## 4. Headline calls

1. **BUY 3 shares AZN.ST (~4,682 SEK) from ISK cash.** Third consecutive sweep
   this has been the Council's top call and the first on which the position is
   above cost. Confidence: **High.** Horizon: **Long.**
2. **SELL all 4 shares ABB.ST (~3,775 SEK).** Rotation on relative merit, not a
   broken business; the "materially better alternative surfaced" clause of its
   own break condition has now been satisfiable for three sweeps. Confidence:
   **Medium.** Horizon: **Medium.**
3. **BUY 1 share META (~5,200 SEK), funded by the ABB proceeds plus ~1,425 SEK
   of ISK cash — and update P3's note, which still earmarks that money for
   GOOGL.** Confidence: **Medium.** Horizon: **Medium.**
4. **Execute P3 (PayPal conversion), still unexecuted after three sweeps.**
   Governance call below. Confidence: **High.** Horizon: **Long.**
5. **No crypto action.** 9.37% vs a 10% target is not a trigger, and Fear&Greed
   73 after a straight-line rally is not the moment to close a 0.63pp gap.
   Confidence: **High.** Horizon: **Medium.**

### Cost of being wrong

| Call | If wrong, realistic downside (SEK) | Recoverable? |
|---|---|---|
| BUY 3 AZN.ST (4,682) | A 25% drawdown on the added shares = ~1,170 SEK. Worst realistic case (pipeline failure, dividend cut) ~50% = ~2,341 SEK. | Yes — 0.5-1.1% of portfolio, and the position remains inside the single-position band. |
| SELL 4 ABB.ST (3,775) | Opportunity cost, not loss. If ABB re-rates +30% over the horizon you forgo ~1,133 SEK. No tax cost (ISK), courtage only. | Yes — fully. You can buy it back. |
| BUY 1 META (~5,200) | 30% drawdown = ~1,560 SEK; a genuine mega-cap de-rating (-50%) = ~2,600 SEK. Add ~5-10% adverse FX on top if the krona strengthens = ~260-520 SEK. | Yes — ~1.2% of portfolio at the -50% case. |
| HOLD VOLV-B.ST | Defensive's scenario (leverage bites, no recovery): a -40% move on 4,420 SEK = ~1,768 SEK. | Yes, but this is the least recoverable of the five — 3.8x net-debt/EBITDA means the downside is non-linear. |
| Execute P3 (~13,575 net) | The 4% spread (~566 SEK) is a certain, known cost. Being wrong here means the money would have been better left in USD/EUR — bounded by FX drift, a few hundred SEK either way. | Yes. |
| No crypto action | If crypto keeps running, you forgo the gain on a 0.63pp underweight ≈ 1,396 SEK of position × the move. If it reverses, you avoided buying at Greed=73. | Yes — trivially small either way. |

### Timing collisions

**None this sweep.** `calendar` reports no earnings or macro events within 45
days for any held ticker. The nearest event is the Riksbank minutes on
**2026-08-25 (tomorrow)**, and no action above is contemplated near it. All
held-name earnings fall in October, beyond the window. If you want to be
fastidious, the Riksbank minutes bear on the Swedish-industrials cluster more
than on anything being bought — and this memo's only Swedish action is a sale,
which the minutes would not obviously change.

---

## 5. Portfolio Governance Council (non-stock decisions)

Five short voices, then the decision. Only one live item this sweep.

### G1 — P3: execute the PayPal conversion

- **The Contrarian:** The strongest reason this fails is that you are paying a
  certain 566 SEK to move money you have not decided how to invest. If the
  converted SEK sits in ISK cash for another month, you have paid a real fee to
  change which idle-cash pile it sits in.
- **First Principles:** Strip the framing. There are two separate questions —
  "should this money be in SEK inside a tax wrapper" (yes, obviously; it earns
  nothing where it is and the inflow recurs every ~2 months forever) and "what
  should it buy" (a separate question with its own answer above). Conflating
  them is what has stalled this for three sweeps.
- **The Expansionist:** Ignore the constraint. The maximum-upside version is to
  fix the *recurring* leg, not the stock: find a routing that avoids the 4%
  spread on every future ~750-1,000 EUR inflow. The user already declined the
  Revolut test (2026-08-17), so the maximum version is unavailable — but note
  that executing the one-off conversion does nothing about the recurring cost,
  which is the larger number over any multi-year horizon.
- **The Outsider:** Described cold: you have roughly 14,000 kronor sitting in a
  payments app, earning nothing, in a currency you do not spend, and you have
  known for six weeks that moving it costs 4%. Every week you wait, the 4% does
  not get cheaper and the money still earns nothing. This is not a close call.
- **The Executor:** Monday: convert both PayPal balances to SEK inside PayPal,
  withdraw to the linked bank account, transfer to Avanza ISK. Then zero the
  two PayPal holdings in `portfolio.json` and close P3.

```
ACTION: EXECUTE (convert + route to ISK)
POSITION: PayPal 1,177.49 USD + 266.88 EUR ≈ 14,140 SEK, 6.4% of total
        portfolio, currently 0% invested and outside every wrapper
TARGET: 0 SEK held at PayPal; ~13,575 SEK net into the Avanza ISK
REASON: (1) it is the highest-leverage single action available per portfolio's
        own rebalancing list, and combined with deploying the 11,288 ISK cash
        moves equity from 71.11% to ~82.3% with zero tax event on either leg;
        (2) the decision was already made 2026-08-17 — this is execution, not
        deliberation; (3) it is unambiguously lever-2 work (fee drag) which is
        otherwise closed, and the recurring inflow means the problem compounds.
THESIS STATUS: INTACT
WHAT CHANGED: nothing about the merits. What changed is that this is now the
        third consecutive sweep it has been listed as decided-pending-execution,
        and this sweep's memo also reassigns its destination (META, not GOOGL —
        see Top 5 #5).
BREAK CONDITION: if PayPal's actual quoted spread at execution exceeds ~6%
        (materially worse than the 4% planning figure), stop and re-open the
        routing question rather than accepting it.
CONFIDENCE: High
HORIZON: Long
```

**Capital-availability premise check.** Verified against this sweep's portfolio
output, not carried from memory: ISK cash is **11,288 SEK**, broker-confirmed
2026-08-23. **Adversarial note on portfolio's own caveat:** portfolio flagged
that `portfolio.json` still carries a stale 11,183 figure needing sync. That is
incorrect — `data/portfolio.json`'s `CASH_SEK (avanza-isk)` holding reads
`"quantity": 11288` with the 2026-08-23 broker confirmation recorded in its
thesis field. No sync is needed. The flag itself is the stale item.

### G2 — no other governance items

Wrapper, fees, cash-allocation mechanics and the target allocation are all
settled and unchanged (see section 3). Gold (P7) is a user-deferred item, not
an open decision — the instrument was reviewed and cleared 2026-08-23 and the
user said "not right now." Not re-litigated here.

---

## 6. Where the agents disagreed

Four real conflicts this sweep. None are averaged away.

1. **Volvo B: Valuation vs Defensive, and it is unresolved.** Valuation reads
   forward P/E 13.77 against trailing 19.46, PEG 1.43 and a ~3.4% FCF yield as
   a recovery already partly priced but still attractive. Defensive reads D/E
   147.3 and net-debt/EBITDA 3.8 on a 7.6% margin as the highest-leverage
   operating company in the entire 43-name universe, going into a +1.45% real
   Swedish policy rate. **Both are reading the same numbers correctly.** The
   difference is whether leverage is a discount or a hazard, and that depends
   entirely on the next quarter's earnings, which do not exist yet.
   **Resolution: HOLD-WATCH. Confidence: Medium. Do not add — the concentration
   constraint settles the add question independently of who is right.**
2. **META vs GOOGL: Quality and Valuation point at different names.** Quality
   says GOOGL is the better business by a wide margin (ROE 48.7 vs 29.8, ROIC
   28.6 vs 18.6, margin 54.8% vs 29.8%, net cash vs modest debt). Valuation says
   META is the better investment (forward multiple falling vs rising, PEG 0.82
   vs 0.93). **This is the exact reason the two voices exist separately, and the
   memo picks the investment over the business, deliberately.** Confidence:
   Medium — it turns on whether GOOGL's 54.8% trailing margin is recurring, and
   no multi-year margin series exists to check.
3. **Macro vs everyone on the two US mega-caps.** Macro downgraded META from
   what the fundamentals alone would support, on the FX ground that buying
   USD-revenue assets with kronor at DXY 118.9 is an unpaid currency bet. **Stated
   plainly rather than buried in a lower conviction score, per the rule.** The
   Chairman overrode it because the objection applies equally to Avanza Global
   (54% of the portfolio, already USD-heavy) and is therefore an argument about
   the whole book, not about this 5,200 SEK trade. Confidence in the override:
   Medium.
4. **Crypto: thesis-review vs macro-regime.** thesis-review keeps ETH INTACT and
   notes the +27.4% move; macro-regime calls Fear&Greed 29 → 73 in under two
   weeks against a strong dollar "froth, not confirmation." **These do not
   actually conflict** — a long-term hold thesis and a near-term add signal are
   different claims, and both agree the answer is "hold, do not add." What *is*
   a real finding is that ETH's stored `key_risks` text cites "Fear" as evidence
   and is now factually wrong. Confidence: High.

**Not a disagreement, but a correction worth recording:** thesis-review reported
that OPEN_ITEMS.md had not yet been updated with the 2026-08-23 second FI
insider pull on ABB. That is wrong — P6 carries a full 2026-08-23 entry
recording it (no escalation, pattern quiet, 2026-09-03 default date closed).
Only `data/company_profiles/ABB.ST.json` is still dated 2026-08-17.

---

## 7. Broken theses requiring a decision

**None BROKEN.** thesis-review's independent re-derivation matched every stored
`thesis_status`, and it says plainly this traces to genuinely unchanged
fundamentals (no new fiscal-quarter data since 2026-08-17), not to a rubber
stamp. Five WEAKENING (SHB-A, INVE-A, ATCO-B, ALFA, ABB), one TOO_EARLY
(VOLV-B), the rest INTACT.

**One thesis file needs an edit, not a decision:** ETH's `key_risks` cites
Fear&Greed 29 / "wrong side of the regime." That input has flipped to 73. Fix
at next full review.

---

## 8. Rebalancing actions

Pulled from `portfolio`, in tax-priority order, with this memo's calls slotted
into them:

- **(a) New contributions (no tax event).** Route 100% of the monthly
  1,000-3,000 SEK into equity.
- **(b) Deploy the 11,288 SEK ISK cash (zero tax event).** This memo assigns
  ~4,682 SEK to AZN.ST and ~1,425 SEK to META, leaving ~5,182 SEK. Portfolio's
  estimate that this closes ~5.1pp of the equity gap holds.
- **(c) AF sales — none available** (only the frozen SEB Osteuropafond).
- **(d) Crypto — no action.** 9.37% vs 10%. Standing reminder: any ETH wallet
  disposal, including a token swap, is a taxable K4 event, and P1 (cost basis)
  is still open.
- **(e) Highest-leverage single action: execute P3.** ~14,140 SEK converted at
  ~4% (~566 SEK cost), net ~13,575 SEK into the ISK. Combined with (b), moves
  equity 71.11% → ~82.3% with zero tax event on either leg.
- **New this sweep: ABB.ST sale (~3,775 SEK, ISK, no tax event)** recycles
  inside the medium tier rather than adding new capital. Note explicitly: the
  position is -0.3% vs cost, so there is **no realized gain**, and
  `profit_recycling_rule` (which governs gains from medium/high tiers flowing to
  the secure tier) does not apply. Redeploying into META is compliant.

---

## 9. Open actions vs open decisions

### Open actions — things you can just go do

| ID | Action | Amount / detail | By when |
|---|---|---|---|
| **P3** | Convert both PayPal balances inside PayPal at ~4%, withdraw, transfer to Avanza ISK | 1,177.49 USD + 266.88 EUR → ~13,575 SEK net | This week — third sweep pending, and the inflow recurs |
| **P9** | Delete the phantom AZN OPENING row in the Excel Transactions tab | Workbook's own README names this exact fix | Before next Excel import |
| **P10** | Confirm: was there one 5,000 SEK deposit or two? | `data/transactions.csv` carries rows dated 2026-08-17 and 2026-08-22 | Reply with the correct date |
| **New** | Place the three orders in section 4 (BUY 3 AZN, SELL 4 ABB, BUY 1 META), plus SHB-A's single share if you want it gone in the same session | ~4,682 buy / ~3,775 sell / ~5,200 buy | Your call on timing; no calendar collisions |
| **Excel** | Paste the updated `data/cache/excel_import/claude_excel_prompt.txt` into your Claude-for-Excel extension | See section 10 | Before next sweep |

### Open decisions — forks where the data does not pick one answer

**D-a — What happens to ABB's slot?** (New, created by this memo's #2.)
- *Option 1: sell ABB, buy META (this memo's call).* Improves both ACT-rated
  concentration rows and buys the best growth-adjusted value in the universe.
  Trade-off: takes on a USD currency bet Macro objected to, and beta 1.243.
- *Option 2: sell ABB, buy more AZN.ST instead.* Simplest, highest-conviction,
  no new FX exposure, improves the defensive-ballast gap. Trade-off: pushes AZN
  toward ~7.3% of portfolio and does nothing for the 100% large-cap row.
- *Option 3: sell ABB, leave the proceeds in ISK cash pending the next
  contribution.* Trade-off: makes the equity underweight worse, and this
  portfolio already has 16.6% cash against a 5% target — the one thing the
  scorecard says most clearly not to do.

**D-b — P5/S6: Investor A cannot be measured.** Second consecutive sweep a
voice has wanted to act on INVE-A and been unable to.
- *Option 1: get the NAV per share off Investor's monthly IR report* (already
  written as Excel request H) and settle it next sweep. Trade-off: ~10 minutes
  of your time, closes S6 permanently.
- *Option 2: sell the 2,027 SEK position on the "unmeasurable + at 96.9% of
  range" argument alone.* Trade-off: sells a reasonable business on absence of
  evidence rather than evidence of absence.
- *Option 3: keep holding and stop re-flagging it.* Trade-off: it will keep
  costing a voice's attention every sweep.

**D-c — Do you have any exclusions?** `investor_profile.json.constraints`
reads "None stated yet." This is why the ESG scorecard row can only ever read
UNKNOWN.
- *Option 1: state none, explicitly.* The row becomes N/A instead of UNKNOWN and
  stops being flagged.
- *Option 2: name specific exclusions* (sectors, countries, ESG lines). Relevant
  right now: EVO.ST (gambling) is this sweep's most interesting contrarian find
  and would be excluded outright under some common lines.

**Still open, unchanged, no new evidence:** P1 (ETH cost basis, blocked on you),
P7 (gold — decided and deferred by you 2026-08-23, not reopened), S1 (Valour
certificate has a ticker, `BTC0E.AS`, but Yahoo's price is ~7x off the real
value — do **not** wire it up as a live feed), S6, S9(a)(b), S12 gap, S13, S15,
S16, S17, S18.

---

## 10. Consolidated Excel-improvement prompt

Appended as a new `COUNCIL DATA REQUESTS` block to
`data/cache/excel_import/claude_excel_prompt.txt` (the file already had content
from the 2026-08-23 import, so this appends rather than overwrites). Nine
requests, deduplicated across the six personas and `portfolio`.

## 11. Excel data gaps — what to fix in the workbook

Sourced verbatim from `data/cache/excel_import/latest-summary.json`. **Note:
no Excel import ran this sweep** — this summary is from the 2026-08-23 dry run
(`master-6.xlsx`), so these are carried, not new.

- **ATCO-B.ST: P/E 2.05 is outside the 3-80 sanity range** — suspect, verify in
  Excel before using it. It would also overwrite a higher-trust broker-terminal
  correction already on file (32.63); not applied.
- **AZN.ST: Excel's P/E 24.4027** would overwrite a higher-trust broker-terminal
  figure (25.49); not applied. Refresh the Stocks data-type cell.
- **INVE-A.ST: Excel's P/E 6.51** would overwrite a higher-trust broker-terminal
  figure (4.76); not applied.
- **AZN.ST quantity: Excel wants 5 → 6.** Blocked by the CONFIRMED marker. This
  is P9 — delete the phantom OPENING row in the Transactions tab.
- **CASH_SEK (avanza-isk): Excel wants 11,288 → 20,366.** Blocked by the
  CONFIRMED marker. Excel's figure is a pre-Valour-purchase balance; the broker
  screen is right. Fix the workbook's cash cell.
- **No 52-week range in Excel for ALFA.ST, ATCO-B.ST, SHB-A.ST, VOLV-B.ST** —
  confirmed data-provider gap for some Nordic-primary tickers, not a formula
  bug. Not blocking.
- **19 Watchlist tickers still carry a space instead of an exchange suffix**
  (NOVO B, ERIC B, ASSA B, INVE B, INDU C, LATO B, KINV B, HEXA B, SEB A, SWED
  A, HM B, SAAB B, EPI B, NIBE B, TEL2 B, SECU B, LIFCO B, ADDT B, GETI B).
  Note the digest *did* resolve several of these correctly this sweep, so the
  fix is partly landed — but any that remain will silently fail every screen.

---

## 12. Data-gap summary for `meta`

Rolled up from the six personas' per-pick flags plus `portfolio`'s own scope.
Ranked by how often a voice was actually blocked by it this sweep.

1. **Currency basis missing from the digest (S17) — blocked the Valuation
   voice's FCF-yield proxy on every non-SEK name, again.** `fcf_b` / `mcap_b`
   produced 0.54% for GOOGL, 0.46% for MSFT, 1.54% for META and 0.12% for AMZN
   — none credible. Only VOLV-B (3.4%) and ERIC-B (9.7%) were usable, because
   both fields are SEK for both. **The fix is already identified in code** (add
   `"currency"` to `DIGEST_COLUMNS` in `scripts/funnel/screen_candidates.py`);
   this is the second consecutive sweep it has degraded a lens.
2. **No 52-week range in the digest — blocked the Contrarian voice's primary
   triage filter.** "Price near a 52-week low" could only be run on the 7 held
   names via the position report; every one of the 36 non-held candidates was
   invisible on this dimension.
3. **Three held tickers are absent from the screen digest entirely: SHB-A.ST,
   INVE-A.ST, ATCO-B.ST.** The Watchlist carries INVE-B.ST and ATCO-A.ST (wrong
   share classes) and no Handelsbanken entry at all. Three of seven individual
   holdings therefore got no numeric triage from any of the six voices and had
   to be reasoned about from `valuation`'s prose alone.
4. **No EV/EBIT and no direct FCF-yield field anywhere** — structural, named in
   `council.md`, still true. `net_debt_to_ebitda` gets close but is not the same
   thing.
5. **No earnings-revision, TAM, or market-share data** — the Growth voice's
   entire "consensus expects earnings up" reading is inferred from the
   forward/trailing P/E gap, which is a proxy, not the thing.
6. **No regulatory-risk data of any kind** — this is what stopped EVO.ST, the
   single most striking screen result this sweep (51.8% margin, net cash, 13.9x
   P/E, 5.05% yield), from being underwritable.
7. **No SEK/DKK rate** — blocked NOVO-B.CO for a second consecutive sweep.
8. **No look-through holdings for Avanza Global (54.2%) or Auto 3 (7.3%)** —
   `portfolio`'s expanded diversification scope covers only 12.6% of the
   portfolio because of this.
9. **No ESG/sustainability field for any holding or candidate** — the scorecard
   row can only read UNKNOWN.
10. **No commodity-price or credit-spread data** — Macro's named structural gap,
    unchanged (V2 Roadmap Phase 5).

**New S-item candidate for `meta` (from this sweep's orchestration, not from a
persona):** `scout`'s first run this sweep (`20260824T061207`) used
`--max-debt-to-equity 2.0` against a field that is on a **percentage-point
scale**, producing zero Passed names. It was corrected and superseded by the
`061349` run. `scripts/funnel/screen_candidates.py`'s own docstring example
already uses `--max-debt-to-equity 150`, confirming the intended scale — so
this is a documentation/validation gap, not a data-fetch bug. Suggested fix:
range-validate the flag at parse time (a D/E threshold below ~5 is almost
certainly a decimal-vs-percent error) and reject with a clear message rather
than silently returning an empty screen. Cheap, and an empty Passed list is
exactly the kind of failure that looks like a quiet market rather than a bug.

---

## 13. Learning notes

- **"Best company" and "best investment" came apart this sweep, and the
  forward-vs-trailing P/E is what separated them.** Alphabet beats Meta on every
  quality measure — 48.7% ROE vs 29.8%, 28.6% ROIC vs 18.6%, 54.8% margin vs
  29.8%, net cash vs modest debt. And yet the memo buys Meta. The reason sits in
  one pair of numbers: Alphabet's multiple goes 17.30 trailing → 23.28 forward,
  Meta's goes 20.70 → 15.85. Trailing P/E divides today's price by the last
  twelve months of *actual* earnings; forward P/E divides it by next year's
  *estimate*. When forward is higher, the denominator is expected to shrink —
  the market is saying earnings will fall. Two companies, same sector, same
  week, opposite messages. Owning the better business at the worse entry is a
  choice you should make knowingly, and this memo chose the other way.
- **A break condition with two clauses can fire on either one, and forgetting
  the second clause is how a position gets held forever.** ABB has been
  HOLD-WATCH for three sweeps because everyone was watching clause one ("insider
  selling continues into a second FI pull"), which was finally tested on
  2026-08-23 and did *not* trigger. But the same condition, written the same
  morning, has a second clause: *"re-test if a materially better-positioned
  alternative surfaces via screening."* That one has been quietly satisfiable
  for weeks. If you only ever check the dramatic clause, a condition designed to
  produce a decision instead produces an indefinite wait. The general habit
  worth building: when a break condition doesn't fire, re-read the whole
  condition, not the part you were watching.
- **Leverage is not a discount, and Volvo is the clearest example this book
  contains.** Volvo's net-debt/EBITDA is 3.8x on a 7.6% profit margin — the
  highest leverage and the thinnest margin of any operating company in the
  43-name universe. The Valuation voice reads the low forward multiple (13.77)
  as the market being cautious; the Defensive voice reads the same price as the
  market being *correct*. What makes leverage different from any other risk is
  that it makes losses **non-linear**: a 10% fall in revenue on a 7.6% margin
  does not cut earnings by 10%, it can erase them, and the debt payment doesn't
  care. That asymmetry is why "cheap on forward P/E" and "safe" are not the same
  sentence, and why the resolution was hold-don't-add rather than buy-the-dip.
- **Selling one share of Handelsbanken is the right call and still not worth
  doing on its own.** Every analytical signal says exit: revenue -3.8%, forward
  P/E above trailing, "underperform" consensus, price at 97.6% of its 52-week
  range, break condition already satisfied. The position is worth 146 SEK. At
  that size, courtage is a material fraction of the proceeds, and the portfolio
  impact of the trade is 0.07%. This is a useful general reflex: before acting
  on a strong signal, check the *size* of the thing it applies to. A correct
  call on a trivial position is not a priority, and the honest instruction is
  "fold it into an order you're placing anyway" rather than either pretending
  it's urgent or pretending the signal isn't there.

---

*Next: `journal` must run to log this sweep.*
